skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
BCR-ABL p210-b3a2 Breakpoint-derived Pentapeptide Vaccine (Code C69082)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: BCR-ABL p210-b3a2 Breakpoint-derived Pentapeptide Vaccine

Definition: A multipeptide vaccine consisting of five peptides derived from the bcr-abl p210-b3a2 breakpoint fusion protein with potential antineoplastic activity. Vaccination with bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl p210-b3a2 breakpoint fusion protein. In chronic myelogenous leukemia (CML), fusion genes typically result from the fusion of either bcr exon b2 or exon b3 to abl exon a2, resulting in either a b3a2 or a b2a2 gene fusion product.

Label: BCR-ABL p210-b3a2 Breakpoint-derived Pentapeptide Vaccine

NCI Thesaurus Code: C69082 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL371859  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BCR-ABL p210-b3a2 Breakpoint-derived Pentapeptide Vaccine
p210-B3A2 Derived Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 543726
PDQ Open Trial Search ID 543726 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C69082
Legacy_Concept_Name BCR-ABL_p210-b3a2_Breakpoint-derived_Pentapeptide_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom